Persista Bio's O2Line system utilizes a unique anti-fibrotic cell capsule and an in-situ oxygen generator to create a long-term implant that regulates blood sugar levels for Type 1 diabetes patients without the need for immunosuppression. This technology eliminates the reliance on conventional therapies such as injections and pumps, significantly improving patient quality of life by normalizing blood glucose levels.
Funding
Funding not disclosed
Founders
Product
Problem
Type 1 diabetes patients currently rely on conventional therapies such as insulin injections and pumps, requiring painstaking daily management to regulate blood sugar levels. These methods do not fully mimic the body's natural processes and can lead to long-term diabetic complications.
Solution
Persista Bio's O2Line system is a long-term cell implant designed to automatically regulate blood sugar levels in Type 1 diabetes patients, mimicking the function of a healthy pancreas. The system utilizes a unique anti-fibrotic cell capsule and an in-situ oxygen generator, eliminating the need for immunosuppression. This approach aims to normalize blood glucose levels, thereby improving patient quality of life by removing the burden of daily injections, pumps, finger sticks, or sensors.
Target Audience
The primary target audience is Type 1 diabetes patients seeking a long-term solution for blood sugar regulation that eliminates the need for conventional therapies.
Features
- Anti-fibrotic cell capsule to protect implanted cells from immune response.
- In-situ oxygen generator to ensure cell viability and function within the implant.
- Long-term implant designed to mimic the body's natural blood sugar regulation processes.
- Eliminates the need for insulin injections, pumps, finger sticks, and sensors.
- Demonstrated normalization of blood glucose levels in preclinical rat trials over 90 days.